Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Anesthesia and Pain MedicineOpen Access

Suspected remimazolam formulation-associated peri-induction anaphylaxis: two cases highlighting diagnostic complexity - Two case reports -

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHyun-Seong LeeMLMin Woo LeeDODaeseok Oh

Discussion

Loading...

Member takes

Overview

Case reports demonstrate diagnostic complexities of remimazolam anaphylaxis in patients with varying conditions, suggesting thorough evaluations are crucial.

Key Points

  • This report aims to highlight the diagnostic challenges of remimazolam formulation-associated anaphylaxis through two case studies.
  • Identified cases among 1,592 patients receiving remimazolam from 2023 to 2025.
  • Analyzed serum tryptase levels and conducted delayed skin testing to assess hypersensitivity.
  • Reviewed patient exposure history and clinical presentations for accurate diagnosis.
  • Case 1 showed persistent hypotension after remimazolam administration; serum tryptase was 38.0 μg/L with negative skin testing.
  • Case 2 experienced hypotension and flushing; serum tryptase remained normal, but delayed skin testing was positive for remimazolam.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a65a3a3d3aea3239cd76b62https://doi.org/10.17085/apm.26622
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Remimazolam-Induced Anaphylaxis After Spinal Anesthesia: A Case Report and Literature Review2026
  2. 2Severe Cardiovascular Collapse Associated With Remimazolam-Based Anesthetic Induction: A Case Series of Three Elderly Patients2026
  3. 3Possible bronchospasm relief following flumazenil administration in a remimazolam-induced Grade III hypersensitivity reaction: a case report2026
  4. 4Severe Anaphylaxis From Remimazolam in a Mastocytosis Cancer Patient: A Case Report2024
  5. 5Remimazolam’s clinical application and safety: A signal detection analysis based on FAERS data and literature support2025